Belzutifan is an inhibitor for HIF-2, and it’s used to treat RCC that’s linked to VHL syndrome. The pill form is a film-coated tablet, and each one’s 40 mg. For adults, you’re supposed to take 120 mg of it once a day.
The drug cuts down on tumor hypoxia signals. Each bottle holds 90 of these tablets. It’s a real game-changer, this drug, because it stops HIF-2 from doing stuff that makes tumors worse and keep coming back.
